A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer

Laurence Albiges, Toni Choueiri, Bernard Escudier, Matthew Galsky, Dan George, Fabian Hofmann, Thomas Lam, Robert Motzer, Peter Mulders, Camillo Porta, Thomas Powles, Cora Sternberg, Axel Bex

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

CONTEXT: The introduction of novel molecular-targeted agents has revolutionised the management of patients with metastatic renal cell carcinoma (mRCC). However, uncertainties remain over sequential or simultaneous combination therapies.

OBJECTIVE: To systematically review relevant literature comparing the clinical effectiveness and harms of different sequencing and combinations of systemic targeted therapies for mRCC.

EVIDENCE ACQUISITION: Relevant databases (including Medline, Cochrane Library, trial registries, and conference proceedings) were searched (January 2000 to September 2013) including only randomised controlled trials (RCTs). Risk of bias assessment was performed. A qualitative and quantitative synthesis of the evidence was presented.

EVIDENCE SYNTHESIS: The literature search identified 5149 articles. A total of 24 studies reporting on 9589 patients were eligible for inclusion; data from four studies were included for meta-analysis. There were generally low risks of bias across studies; however, clinical and methodological heterogeneity prevented pooling of data for most studies. Overall, the data showed several targeted therapies were associated with an improvement in progression-free survival in patients with mRCC. There were limited data from RCTs regarding the issue of sequencing; studies on combination therapies have been hampered by difficulties with tolerability and safety.

CONCLUSIONS: Although the role of vascular endothelial growth factor/vascular endothelial growth factor receptor targeting therapies and mammalian target of rapamycin inhibition in the management of mRCC is now established, limited reliable data are available regarding sequencing and combination therapies. Although data from retrospective cohort studies suggest a potential benefit for sequencing systemic therapies, significant uncertainties remain. Presently, mRCC systemic treatment should follow international guidelines (such as the European Society for Medical Oncology, National Comprehensive Cancer Network, and European Association of Urology) for patients fit to receive several lines of systemic therapies.

PATIENT SUMMARY: We thoroughly examined the literature on the benefits and harms of combining drugs for the treatment of kidney cancer that has spread and on the sequence in which the drugs should be given.

Original languageEnglish
Pages (from-to)100-110
Number of pages11
JournalEuropean Urology
Volume67
Issue number1
Early online date30 Apr 2014
DOIs
Publication statusPublished - Jan 2015

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Therapeutics
Uncertainty
Meta-Analysis
Randomized Controlled Trials
Vascular Endothelial Growth Factor Receptor
Sirolimus
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Libraries
Disease-Free Survival
Registries
Cohort Studies
Retrospective Studies
Databases
Guidelines
Safety

Keywords

  • renal cell carcinoma
  • tyrosine kinase inhibitor
  • sequence of systemic therapies
  • combination of systemic therapies

Cite this

Albiges, L., Choueiri, T., Escudier, B., Galsky, M., George, D., Hofmann, F., ... Bex, A. (2015). A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. European Urology, 67(1), 100-110. https://doi.org/10.1016/j.eururo.2014.04.006

A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. / Albiges, Laurence; Choueiri, Toni; Escudier, Bernard; Galsky, Matthew; George, Dan; Hofmann, Fabian; Lam, Thomas; Motzer, Robert; Mulders, Peter; Porta, Camillo; Powles, Thomas; Sternberg, Cora; Bex, Axel.

In: European Urology, Vol. 67, No. 1, 01.2015, p. 100-110.

Research output: Contribution to journalArticle

Albiges, L, Choueiri, T, Escudier, B, Galsky, M, George, D, Hofmann, F, Lam, T, Motzer, R, Mulders, P, Porta, C, Powles, T, Sternberg, C & Bex, A 2015, 'A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer', European Urology, vol. 67, no. 1, pp. 100-110. https://doi.org/10.1016/j.eururo.2014.04.006
Albiges, Laurence ; Choueiri, Toni ; Escudier, Bernard ; Galsky, Matthew ; George, Dan ; Hofmann, Fabian ; Lam, Thomas ; Motzer, Robert ; Mulders, Peter ; Porta, Camillo ; Powles, Thomas ; Sternberg, Cora ; Bex, Axel. / A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. In: European Urology. 2015 ; Vol. 67, No. 1. pp. 100-110.
@article{37ef76a7b6b14eca996647646b19bc9d,
title = "A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer",
abstract = "CONTEXT: The introduction of novel molecular-targeted agents has revolutionised the management of patients with metastatic renal cell carcinoma (mRCC). However, uncertainties remain over sequential or simultaneous combination therapies.OBJECTIVE: To systematically review relevant literature comparing the clinical effectiveness and harms of different sequencing and combinations of systemic targeted therapies for mRCC.EVIDENCE ACQUISITION: Relevant databases (including Medline, Cochrane Library, trial registries, and conference proceedings) were searched (January 2000 to September 2013) including only randomised controlled trials (RCTs). Risk of bias assessment was performed. A qualitative and quantitative synthesis of the evidence was presented.EVIDENCE SYNTHESIS: The literature search identified 5149 articles. A total of 24 studies reporting on 9589 patients were eligible for inclusion; data from four studies were included for meta-analysis. There were generally low risks of bias across studies; however, clinical and methodological heterogeneity prevented pooling of data for most studies. Overall, the data showed several targeted therapies were associated with an improvement in progression-free survival in patients with mRCC. There were limited data from RCTs regarding the issue of sequencing; studies on combination therapies have been hampered by difficulties with tolerability and safety.CONCLUSIONS: Although the role of vascular endothelial growth factor/vascular endothelial growth factor receptor targeting therapies and mammalian target of rapamycin inhibition in the management of mRCC is now established, limited reliable data are available regarding sequencing and combination therapies. Although data from retrospective cohort studies suggest a potential benefit for sequencing systemic therapies, significant uncertainties remain. Presently, mRCC systemic treatment should follow international guidelines (such as the European Society for Medical Oncology, National Comprehensive Cancer Network, and European Association of Urology) for patients fit to receive several lines of systemic therapies.PATIENT SUMMARY: We thoroughly examined the literature on the benefits and harms of combining drugs for the treatment of kidney cancer that has spread and on the sequence in which the drugs should be given.",
keywords = "renal cell carcinoma, tyrosine kinase inhibitor, sequence of systemic therapies, combination of systemic therapies",
author = "Laurence Albiges and Toni Choueiri and Bernard Escudier and Matthew Galsky and Dan George and Fabian Hofmann and Thomas Lam and Robert Motzer and Peter Mulders and Camillo Porta and Thomas Powles and Cora Sternberg and Axel Bex",
note = "Copyright {\circledC} 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = "1",
doi = "10.1016/j.eururo.2014.04.006",
language = "English",
volume = "67",
pages = "100--110",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer

AU - Albiges, Laurence

AU - Choueiri, Toni

AU - Escudier, Bernard

AU - Galsky, Matthew

AU - George, Dan

AU - Hofmann, Fabian

AU - Lam, Thomas

AU - Motzer, Robert

AU - Mulders, Peter

AU - Porta, Camillo

AU - Powles, Thomas

AU - Sternberg, Cora

AU - Bex, Axel

N1 - Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2015/1

Y1 - 2015/1

N2 - CONTEXT: The introduction of novel molecular-targeted agents has revolutionised the management of patients with metastatic renal cell carcinoma (mRCC). However, uncertainties remain over sequential or simultaneous combination therapies.OBJECTIVE: To systematically review relevant literature comparing the clinical effectiveness and harms of different sequencing and combinations of systemic targeted therapies for mRCC.EVIDENCE ACQUISITION: Relevant databases (including Medline, Cochrane Library, trial registries, and conference proceedings) were searched (January 2000 to September 2013) including only randomised controlled trials (RCTs). Risk of bias assessment was performed. A qualitative and quantitative synthesis of the evidence was presented.EVIDENCE SYNTHESIS: The literature search identified 5149 articles. A total of 24 studies reporting on 9589 patients were eligible for inclusion; data from four studies were included for meta-analysis. There were generally low risks of bias across studies; however, clinical and methodological heterogeneity prevented pooling of data for most studies. Overall, the data showed several targeted therapies were associated with an improvement in progression-free survival in patients with mRCC. There were limited data from RCTs regarding the issue of sequencing; studies on combination therapies have been hampered by difficulties with tolerability and safety.CONCLUSIONS: Although the role of vascular endothelial growth factor/vascular endothelial growth factor receptor targeting therapies and mammalian target of rapamycin inhibition in the management of mRCC is now established, limited reliable data are available regarding sequencing and combination therapies. Although data from retrospective cohort studies suggest a potential benefit for sequencing systemic therapies, significant uncertainties remain. Presently, mRCC systemic treatment should follow international guidelines (such as the European Society for Medical Oncology, National Comprehensive Cancer Network, and European Association of Urology) for patients fit to receive several lines of systemic therapies.PATIENT SUMMARY: We thoroughly examined the literature on the benefits and harms of combining drugs for the treatment of kidney cancer that has spread and on the sequence in which the drugs should be given.

AB - CONTEXT: The introduction of novel molecular-targeted agents has revolutionised the management of patients with metastatic renal cell carcinoma (mRCC). However, uncertainties remain over sequential or simultaneous combination therapies.OBJECTIVE: To systematically review relevant literature comparing the clinical effectiveness and harms of different sequencing and combinations of systemic targeted therapies for mRCC.EVIDENCE ACQUISITION: Relevant databases (including Medline, Cochrane Library, trial registries, and conference proceedings) were searched (January 2000 to September 2013) including only randomised controlled trials (RCTs). Risk of bias assessment was performed. A qualitative and quantitative synthesis of the evidence was presented.EVIDENCE SYNTHESIS: The literature search identified 5149 articles. A total of 24 studies reporting on 9589 patients were eligible for inclusion; data from four studies were included for meta-analysis. There were generally low risks of bias across studies; however, clinical and methodological heterogeneity prevented pooling of data for most studies. Overall, the data showed several targeted therapies were associated with an improvement in progression-free survival in patients with mRCC. There were limited data from RCTs regarding the issue of sequencing; studies on combination therapies have been hampered by difficulties with tolerability and safety.CONCLUSIONS: Although the role of vascular endothelial growth factor/vascular endothelial growth factor receptor targeting therapies and mammalian target of rapamycin inhibition in the management of mRCC is now established, limited reliable data are available regarding sequencing and combination therapies. Although data from retrospective cohort studies suggest a potential benefit for sequencing systemic therapies, significant uncertainties remain. Presently, mRCC systemic treatment should follow international guidelines (such as the European Society for Medical Oncology, National Comprehensive Cancer Network, and European Association of Urology) for patients fit to receive several lines of systemic therapies.PATIENT SUMMARY: We thoroughly examined the literature on the benefits and harms of combining drugs for the treatment of kidney cancer that has spread and on the sequence in which the drugs should be given.

KW - renal cell carcinoma

KW - tyrosine kinase inhibitor

KW - sequence of systemic therapies

KW - combination of systemic therapies

U2 - 10.1016/j.eururo.2014.04.006

DO - 10.1016/j.eururo.2014.04.006

M3 - Article

C2 - 24841777

VL - 67

SP - 100

EP - 110

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -